Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous natural killer cell injection E10H
- Development stage
- Unknown
- Lead developer
- Guangzhou Double Bioproducts
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
E10H is an autologous natural killer (NK) cell therapy developed by Guangzhou Double Bioproducts. The treatment involves the isolation of NK cells from a patient's own peripheral blood, followed by ex vivo expansion and activation before re-infusion. NK cells are innate immune effectors that can recognize and eliminate tumor cells through the release of cytotoxic granules (perforin and granzymes) and the secretion of cytokines like interferon-gamma. E10H is currently being evaluated in Phase II clinical trials in China as a first-line treatment for advanced gastrointestinal cancers, including gastric adenocarcinoma and colorectal cancer. In these studies, it is administered in combination with IgG1 antibodies and standard chemotherapy to potentially enhance anti-tumor activity through antibody-dependent cellular cytotoxicity (ADCC) and synergistic immune activation.
- Other names
- E10H autologous NK cellsE-10H autologous NK cellsE 10H autologous NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on autologous natural killer cell injection E10H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous natural killer cell injection E10H.